4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Haloperidol is combined with Gamma Hydroxybutyric Acid.
4-Phenylbutyric Acid
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Haloperidol.
Abiraterone
The serum concentration of Haloperidol can be increased when it is combined with Abiraterone.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Haloperidol.
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Haloperidol.
Acepromazine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Acepromazine.
Advertisement
Aceprometazine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Aceprometazine.
Acetaminophen
The metabolism of Acetaminophen can be decreased when combined with Haloperidol.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Haloperidol.
Advertisement
Acetyl Sulfisoxazole
The metabolism of Haloperidol can be decreased when combined with Acetyl sulfisoxazole.
Acetylcholine
The metabolism of Acetylcholine can be decreased when combined with Haloperidol.
Acetylcholine Chloride
The metabolism of Acetylcholine can be decreased when combined with Haloperidol.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Haloperidol.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Haloperidol.
Ajmaline
The metabolism of Ajmaline can be decreased when combined with Haloperidol.
Albuterol
Salbutamol may increase the QTc-prolonging activities of Haloperidol.
Alfaxalone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Haloperidol is combined with Alfentanil.
Alfuzosin
Alfuzosin may increase the QTc-prolonging activities of Haloperidol.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Haloperidol.
Almotriptan
The metabolism of Almotriptan can be decreased when combined with Haloperidol.
Alogliptin
The metabolism of Alogliptin can be decreased when combined with Haloperidol.
Alphaprodine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol.
Alprenolol
The metabolism of Alprenolol can be decreased when combined with Haloperidol.
Amantadine
The therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine.
Aminopyrine
The metabolism of Aminophenazone can be decreased when combined with Haloperidol.
Amiodarone
Haloperidol may increase the QTc-prolonging activities of Amiodarone.
Amisulpride
Haloperidol may increase the antipsychotic activities of Amisulpride.
Amitriptyline
The metabolism of Amitriptyline can be decreased when combined with Haloperidol.
Amobarbital
The risk or severity of adverse effects can be increased when Haloperidol is combined with Amobarbital.
Amoxapine
The metabolism of Amoxapine can be decreased when combined with Haloperidol.
Amphetamine
The metabolism of Amphetamine can be decreased when combined with Haloperidol.
Amprenavir
The metabolism of Amprenavir can be decreased when combined with Haloperidol.
Amsacrine
The metabolism of Amsacrine can be decreased when combined with Haloperidol.
Anagrelide
Haloperidol may increase the QTc-prolonging activities of Anagrelide.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Haloperidol.
Apalutamide
The serum concentration of Haloperidol can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol.
Apomorphine
The therapeutic efficacy of Haloperidol can be decreased when used in combination with Apomorphine.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Haloperidol.
Aprepitant
The serum concentration of Haloperidol can be increased when it is combined with Aprepitant.
Aprindine
The metabolism of Aprindine can be decreased when combined with Haloperidol.
Arformoterol
The metabolism of Arformoterol can be decreased when combined with Haloperidol.
Aripiprazole
Aripiprazole may increase the QTc-prolonging activities of Haloperidol.
Armodafinil
The metabolism of Haloperidol can be decreased when combined with Armodafinil.
Arsenic Trioxide
Haloperidol may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Haloperidol may increase the QTc-prolonging activities of Artemether.
Articaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Articaine.
Asenapine
Haloperidol may increase the QTc-prolonging activities of Asenapine.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Haloperidol.
Astemizole
The metabolism of Astemizole can be decreased when combined with Haloperidol.
Asunaprevir
The serum concentration of Asunaprevir can be increased when it is combined with Haloperidol.
Atazanavir
The metabolism of Haloperidol can be decreased when combined with Atazanavir.
Atomoxetine
The metabolism of Haloperidol can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Haloperidol is combined with Atorvastatin.
Azelastine
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azithromycin
Azithromycin may increase the QTc-prolonging activities of Haloperidol.
Baclofen
The risk or severity of adverse effects can be increased when Haloperidol is combined with Baclofen.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Haloperidol.
Barbital
The risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital.
Bedaquiline
Haloperidol may increase the QTc-prolonging activities of Bedaquiline.
Benoxinate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Oxybuprocaine.
Benperidol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Benzocaine.
Benzoic Acid
The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Haloperidol.
Benzphetamine
Haloperidol may decrease the stimulatory activities of Benzphetamine.
Benztropine
The metabolism of Benzatropine can be decreased when combined with Haloperidol.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Haloperidol.
Benzyl Alcohol
The metabolism of Benzyl alcohol can be decreased when combined with Haloperidol.
Bepridil
The metabolism of Bepridil can be decreased when combined with Haloperidol.
Betaxolol
The metabolism of Betaxolol can be decreased when combined with Haloperidol.
Bisoprolol
The metabolism of Bisoprolol can be decreased when combined with Haloperidol.
Boceprevir
The metabolism of Haloperidol can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Haloperidol can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Haloperidol can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Haloperidol can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Haloperidol.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Haloperidol.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Haloperidol.
Brexpiprazole
The serum concentration of Brexpiprazole can be increased when it is combined with Haloperidol.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Bromazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Bromazepam.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Haloperidol.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Haloperidol.
Bromperidol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Bromperidol.
Brompheniramine
The metabolism of Brompheniramine can be decreased when combined with Haloperidol.
Brotizolam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Brotizolam.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Haloperidol.
Bupivacaine
The metabolism of Bupivacaine can be decreased when combined with Haloperidol.
Buprenorphine
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The metabolism of Haloperidol can be decreased when combined with Bupropion.
Buserelin
Buserelin may increase the QTc-prolonging activities of Haloperidol.
Buspirone
The metabolism of Buspirone can be decreased when combined with Haloperidol.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol.
Butalbital
The risk or severity of adverse effects can be increased when Haloperidol is combined with Butalbital.
Butamben
The risk or severity of adverse effects can be increased when Haloperidol is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Haloperidol is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Butorphanol.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Haloperidol.
Caffeine
The metabolism of Haloperidol can be decreased when combined with Caffeine.
Capecitabine
The metabolism of Haloperidol can be decreased when combined with Capecitabine.
Captopril
The metabolism of Captopril can be decreased when combined with Haloperidol.
Carbamazepine
The metabolism of Haloperidol can be increased when combined with Carbamazepine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Carbinoxamine.
Cariprazine
The metabolism of Cariprazine can be decreased when combined with Haloperidol.
Carisoprodol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Carisoprodol.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Haloperidol.
Carteolol
The metabolism of Carteolol can be decreased when combined with Haloperidol.
Carvedilol
The metabolism of Carvedilol can be decreased when combined with Haloperidol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.
Cephalexin
The metabolism of Cephalexin can be decreased when combined with Haloperidol.
CEPHALEXIN ANHYDROUS
The metabolism of Cephalexin can be decreased when combined with Haloperidol.
Ceritinib
The serum concentration of Haloperidol can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Haloperidol.
Cetirizine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Cetirizine.
Cevimeline
The metabolism of Cevimeline can be decreased when combined with Haloperidol.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Chloral hydrate.
Chloramphenicol
The metabolism of Haloperidol can be decreased when combined with Chloramphenicol.
Chlordiazepoxide
The metabolism of Chlordiazepoxide can be decreased when combined with Haloperidol.
Chlormethiazole
The risk or severity of adverse effects can be increased when Haloperidol is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Chloroprocaine.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Haloperidol.
Chlorpheniramine
The metabolism of Chlorphenamine can be decreased when combined with Haloperidol.
CHLORPHENIRAMINE POLISTIREX
The metabolism of Chlorphenamine can be decreased when combined with Haloperidol.
Chlorpromazine
Chlorpromazine may increase the QTc-prolonging activities of Haloperidol.
Chlorprothixene
The risk or severity of adverse effects can be increased when Haloperidol is combined with Chlorprothixene.
Chlorzoxazone
The metabolism of Chlorzoxazone can be decreased when combined with Haloperidol.
Cholecalciferol
The metabolism of Haloperidol can be decreased when combined with Cholecalciferol.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Haloperidol.
Cilostazol
The metabolism of Cilostazol can be decreased when combined with Haloperidol.
Cimetidine
The metabolism of Haloperidol can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Haloperidol can be decreased when combined with Cinacalcet.
Cinnarizine
The metabolism of Cinnarizine can be decreased when combined with Haloperidol.
Ciprofloxacin
Haloperidol may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Haloperidol may increase the QTc-prolonging activities of Cisapride.
Citalopram
Haloperidol may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
The metabolism of Haloperidol can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Haloperidol can be decreased when combined with Clemastine.
Clevidipine
The metabolism of Clevidipine can be decreased when combined with Haloperidol.
Clevidipine butyrate
The metabolism of Clevidipine can be decreased when combined with Haloperidol.
Clidinium
The risk or severity of adverse effects can be increased when Haloperidol is combined with Clidinium.
Clidinium bromide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Clidinium.
Clobazam
The metabolism of Haloperidol can be decreased when combined with Clobazam.
Clomipramine
The metabolism of Clomipramine can be decreased when combined with Haloperidol.
Clonazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Clonazepam.
Clonidine
The metabolism of Clonidine can be decreased when combined with Haloperidol.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Haloperidol.
Clorazepate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Clorazepate.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Haloperidol is combined with Clorazepate.
Clotrimazole
The metabolism of Haloperidol can be decreased when combined with Clotrimazole.
Clozapine
Clozapine may increase the QTc-prolonging activities of Haloperidol.
Cobicistat
The serum concentration of Haloperidol can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Haloperidol can be decreased when combined with Cocaine.
Codeine
The therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.
Codeine Anhydrous
The therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.
CODEINE POLISTIREX
The therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Haloperidol.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Haloperidol.
Crisaborole
The metabolism of Haloperidol can be decreased when combined with Crisaborole.
Crizotinib
Haloperidol may increase the QTc-prolonging activities of Crizotinib.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Haloperidol.
Cyclizine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Cyclizine.
Cyclobenzaprine
The metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.
Cyclophosphamide
The metabolism of Cyclophosphamide can be decreased when combined with Haloperidol.
Cyclophosphamide Anhydrous
The metabolism of Cyclophosphamide can be decreased when combined with Haloperidol.
Cyclosporine
The metabolism of Haloperidol can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Cyproheptadine.
Cyproterone Acetate
The serum concentration of Haloperidol can be decreased when it is combined with Cyproterone acetate.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Haloperidol.
Dabrafenib
The serum concentration of Haloperidol can be decreased when it is combined with Dabrafenib.
Dantrolene
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dantrolene.
Dapagliflozin
The metabolism of Dapagliflozin can be decreased when combined with Haloperidol.
Dapiprazole
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dapiprazole.
Darifenacin
The metabolism of Haloperidol can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Haloperidol can be increased when it is combined with Darunavir.
Dasabuvir
The metabolism of Dasabuvir can be decreased when combined with Haloperidol.
Dasatinib
The serum concentration of Haloperidol can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Haloperidol can be increased when it is combined with Dasatinib.
Debrisoquin
The metabolism of Debrisoquin can be decreased when combined with Haloperidol.
Deferasirox
The serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.
Degarelix
Degarelix may increase the QTc-prolonging activities of Haloperidol.
Delavirdine
The metabolism of Haloperidol can be decreased when combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Haloperidol is combined with Desflurane.
Desipramine
The metabolism of Desipramine can be decreased when combined with Haloperidol.
Desloratadine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Desloratadine.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Desvenlafaxine.
Deutetrabenazine
Haloperidol may increase the QTc-prolonging activities of Deutetrabenazine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dexbrompheniramine.
Dexchlorpheniramine maleate
The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Haloperidol.
Dexfenfluramine
The metabolism of Dexfenfluramine can be decreased when combined with Haloperidol.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dexmedetomidine.
Dexmethylphenidate
The metabolism of Dexmethylphenidate can be decreased when combined with Haloperidol.
Dextroamphetamine
The metabolism of Dextroamphetamine can be decreased when combined with Haloperidol.
Dextromethorphan
The metabolism of Dextromethorphan can be decreased when combined with Haloperidol.
Dextromoramide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Diazepam.
Dibucaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Cinchocaine.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Haloperidol.
Diethylpropion
Haloperidol may decrease the stimulatory activities of Diethylpropion.
Difenoxin
The risk or severity of adverse effects can be increased when Haloperidol is combined with Difenoxin.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.
Dihydrocodeine
The metabolism of Dihydrocodeine can be decreased when combined with Haloperidol.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Haloperidol.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Haloperidol.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Haloperidol.
Diltiazem
The metabolism of Haloperidol can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dimenhydrinate.
Diphenhydramine
The metabolism of Diphenhydramine can be decreased when combined with Haloperidol.
Diphenoxylate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Diphenoxylate.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol.
Disopyramide
Haloperidol may increase the QTc-prolonging activities of Disopyramide.
Dofetilide
Haloperidol may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Haloperidol may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Haloperidol may increase the QTc-prolonging activities of Domperidone.
Donepezil
The metabolism of Donepezil can be decreased when combined with Haloperidol.
Dopamine
The metabolism of Dopamine can be decreased when combined with Haloperidol.
Dothiepin
The metabolism of Haloperidol can be decreased when combined with Dosulepin.
Doxazosin
The metabolism of Doxazosin can be decreased when combined with Haloperidol.
Doxepin
The metabolism of Doxepin can be decreased when combined with Haloperidol.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Haloperidol.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Haloperidol.
Doxycycline
The metabolism of Haloperidol can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Haloperidol can be decreased when combined with Doxycycline.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Dronedarone
Haloperidol may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Haloperidol.
Duloxetine
The metabolism of Haloperidol can be decreased when combined with Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Haloperidol.
Efavirenz
The metabolism of Haloperidol can be decreased when combined with Efavirenz.
Eletriptan
The metabolism of Eletriptan can be decreased when combined with Haloperidol.
Eliglustat
The serum concentration of Eliglustat can be increased when it is combined with Haloperidol.
Enasidenib
The metabolism of Enasidenib can be decreased when combined with Haloperidol.
Encainide
The metabolism of Encainide can be decreased when combined with Haloperidol.
Enflurane
The risk or severity of adverse effects can be increased when Haloperidol is combined with Enflurane.
Entacapone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Entacapone.
Enzalutamide
The serum concentration of Haloperidol can be decreased when it is combined with Enzalutamide.
Epinastine
The metabolism of Epinastine can be decreased when combined with Haloperidol.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Haloperidol.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Haloperidol.
Eribulin
Eribulin may increase the QTc-prolonging activities of Haloperidol.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Haloperidol.
Erythromycin
Erythromycin may increase the QTc-prolonging activities of Haloperidol.
Escitalopram
Haloperidol may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine Acetate
The metabolism of Haloperidol can be decreased when combined with Eslicarbazepine acetate.
Esomeprazole
The metabolism of Haloperidol can be decreased when combined with Esomeprazole.
Estazolam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Estazolam.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Haloperidol.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Haloperidol.
Ethanol
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethchlorvynol.
Ethosuximide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethosuximide.
Ethotoin
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethotoin.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl loflazepate.
Ethylmorphine
The metabolism of Ethylmorphine can be decreased when combined with Haloperidol.
Etidocaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Etifoxine.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Haloperidol.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Haloperidol.
Etomidate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Etomidate.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Haloperidol.
Etravirine
The metabolism of Haloperidol can be decreased when combined with Etravirine.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Haloperidol.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Haloperidol.
Ezogabine
Ezogabine may increase the QTc-prolonging activities of Haloperidol.
Famotidine
Famotidine may increase the QTc-prolonging activities of Haloperidol.
Felbamate
Felbamate may increase the QTc-prolonging activities of Haloperidol.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Haloperidol.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Haloperidol.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Haloperidol.
Fentanyl
The risk or severity of adverse effects can be increased when Haloperidol is combined with Fentanyl.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Haloperidol.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.
Fexofenadine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Fexofenadine.
Fingolimod
The metabolism of Fingolimod can be decreased when combined with Haloperidol.
Flecainide
Haloperidol may increase the QTc-prolonging activities of Flecainide.
Flibanserin
The risk or severity of adverse effects can be increased when Haloperidol is combined with Flibanserin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Haloperidol.
Floxuridine
The metabolism of Haloperidol can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Haloperidol can be decreased when combined with Fluconazole.
Flunarizine
The metabolism of Flunarizine can be decreased when combined with Haloperidol.
Flunitrazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Flunitrazepam.
Fluorouracil
The metabolism of Haloperidol can be decreased when combined with Fluorouracil.
Fluoxetine
Fluoxetine may increase the QTc-prolonging activities of Haloperidol.
Flupenthixol
Haloperidol may increase the QTc-prolonging activities of Flupentixol.
Fluphenazine
The metabolism of Fluphenazine can be decreased when combined with Haloperidol.
Flurazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Flurazepam.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Haloperidol.
Fluspirilene
The risk or severity of adverse effects can be increased when Haloperidol is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Fluticasone propionate.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Haloperidol.
Fluvoxamine
The serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.
Formoterol
The metabolism of Formoterol can be decreased when combined with Haloperidol.
Fosamprenavir
The metabolism of Haloperidol can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Haloperidol can be increased when it is combined with Fosaprepitant.
Foscarnet
Foscarnet may increase the QTc-prolonging activities of Haloperidol.
Fosphenytoin
The metabolism of Haloperidol can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Fospropofol.
Frovatriptan
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Haloperidol.
Fusidate
The serum concentration of Haloperidol can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Haloperidol can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin Enacarbil.
Gadobenate
Haloperidol may increase the QTc-prolonging activities of Gadobenic acid.
Galantamine
The metabolism of Galantamine can be decreased when combined with Haloperidol.
Gefitinib
The metabolism of Gefitinib can be decreased when combined with Haloperidol.
Gemfibrozil
The metabolism of Haloperidol can be decreased when combined with Gemfibrozil.
Gemifloxacin
Haloperidol may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Haloperidol may increase the QTc-prolonging activities of Gemifloxacin.
Glutethimide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Glutethimide.
Glycerol Phenylbutyrate
The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Haloperidol.
Glycopyrronium
The serum concentration of Haloperidol can be decreased when it is combined with Glycopyrronium.
Goserelin
Goserelin may increase the QTc-prolonging activities of Haloperidol.
Granisetron
Haloperidol may increase the QTc-prolonging activities of Granisetron.
Guanfacine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Guanfacine.
Halazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Halazepam.
Halofantrine
The metabolism of Halofantrine can be decreased when combined with Haloperidol.
Halothane
The metabolism of Halothane can be decreased when combined with Haloperidol.
Heroin
The risk or severity of adverse effects can be increased when Haloperidol is combined with Heroin.
Hexobarbital
The risk or severity of adverse effects can be increased when Haloperidol is combined with Hexobarbital.
Histrelin
Histrelin may increase the QTc-prolonging activities of Haloperidol.
Hydrocodone
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone
The metabolism of Hydromorphone can be decreased when combined with Haloperidol.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Hypoxis hemerocallidea root extract
The serum concentration of Haloperidol can be decreased when it is combined with St. John's Wort.
Ibandronate
Ibandronate may increase the QTc-prolonging activities of Haloperidol.
Ibandronic Acid
Ibandronate may increase the QTc-prolonging activities of Haloperidol.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Haloperidol.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Haloperidol.
Ibutilide
Haloperidol may increase the QTc-prolonging activities of Ibutilide.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Haloperidol.
Idarubicin
The metabolism of Idarubicin can be decreased when combined with Haloperidol.
Idelalisib
The metabolism of Haloperidol can be decreased when combined with Idelalisib.
Iloperidone
Haloperidol may increase the QTc-prolonging activities of Iloperidone.
Imatinib
The metabolism of Haloperidol can be decreased when combined with Imatinib.
Imipramine
The metabolism of Imipramine can be decreased when combined with Haloperidol.
Indacaterol
Indacaterol may increase the QTc-prolonging activities of Haloperidol.
Indapamide
Indapamide may increase the QTc-prolonging activities of Haloperidol.
Indinavir
The metabolism of Haloperidol can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Haloperidol can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Haloperidol.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.
Ipecac
The metabolism of Ipecac can be decreased when combined with Haloperidol.
Ipratropium
The metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.
Ipratropium cation
The metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.
Irbesartan
The metabolism of Haloperidol can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Haloperidol can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Haloperidol can be decreased when combined with Isavuconazonium.
Isocarboxazid
The therapeutic efficacy of Haloperidol can be increased when used in combination with Isocarboxazid.
Isoflurane
The risk or severity of adverse effects can be increased when Haloperidol is combined with Isoflurane.
Isoniazid
The metabolism of Haloperidol can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Haloperidol can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Haloperidol can be decreased when combined with Itraconazole.
Ivabradine
Ivabradine may increase the QTc-prolonging activities of Haloperidol.
Ivacaftor
The serum concentration of Haloperidol can be increased when it is combined with Ivacaftor.
Ixazomib
The metabolism of Ixazomib can be decreased when combined with Haloperidol.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Haloperidol.
Ketamine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ketamine.
Ketazolam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ketazolam.
Ketoconazole
The metabolism of Haloperidol can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Haloperidol.
Labetalol
The metabolism of Labetalol can be decreased when combined with Haloperidol.
Lamotrigine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Lamotrigine.
Lapatinib
Lapatinib may increase the QTc-prolonging activities of Haloperidol.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Haloperidol.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Haloperidol.
Lenvatinib
Haloperidol may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Haloperidol may increase the QTc-prolonging activities of Lenvatinib.
Letermovir
The metabolism of Letermovir can be decreased when combined with Haloperidol.
Leuprolide
Leuprolide may increase the QTc-prolonging activities of Haloperidol.
Levetiracetam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Levetiracetam.
Levobupivacaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Levobupivacaine.
Levocabastine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Levocetirizine.
Levodopa
The therapeutic efficacy of Haloperidol can be decreased when used in combination with Levodopa.
Levofloxacin
Haloperidol may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Haloperidol may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl
The risk or severity of adverse effects can be increased when Haloperidol is combined with Levomethadyl Acetate.
Levomilnacipran
The metabolism of Levomilnacipran can be decreased when combined with Haloperidol.
Levorphanol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Levorphanol.
Lidocaine
The metabolism of Haloperidol can be decreased when combined with Lidocaine.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Haloperidol.
Linezolid
The risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol.
Lisdexamfetamine
Haloperidol may decrease the stimulatory activities of Lisdexamfetamine.
Lisdexamfetamine Dimesylate
Haloperidol may decrease the stimulatory activities of Lisdexamfetamine.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Haloperidol.
Lithium
Lithium may increase the neurotoxic activities of Haloperidol.
Lithium Cation
Lithium may increase the neurotoxic activities of Haloperidol.
Lofexidine
The therapeutic efficacy of Haloperidol can be increased when used in combination with Lofexidine.
Lomustine
The metabolism of Lomustine can be decreased when combined with Haloperidol.
Loperamide
The metabolism of Loperamide can be decreased when combined with Haloperidol.
Lopinavir
Haloperidol may increase the QTc-prolonging activities of Lopinavir.
Loratadine
The metabolism of Loratadine can be decreased when combined with Haloperidol.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol.
Lorcaserin
The metabolism of Lorcaserin can be decreased when combined with Haloperidol.
Lormetazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Lormetazepam.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Haloperidol.
Losartan
The metabolism of Haloperidol can be decreased when combined with Losartan.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Haloperidol.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Haloperidol.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Haloperidol.
Luliconazole
The serum concentration of Haloperidol can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Haloperidol can be decreased when it is combined with Lumacaftor.
Lumefantrine
Haloperidol may increase the QTc-prolonging activities of Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone.
Macimorelin
Haloperidol may increase the QTc-prolonging activities of Macimorelin.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Haloperidol.
Magnesium Sulfate
The therapeutic efficacy of Haloperidol can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Haloperidol can be increased when used in combination with Magnesium sulfate.
Manidipine
The metabolism of Haloperidol can be decreased when combined with Manidipine.
Maprotiline
The metabolism of Maprotiline can be decreased when combined with Haloperidol.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Haloperidol.
Meclizine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Meclizine.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.
Mefloquine
Mefloquine may increase the QTc-prolonging activities of Haloperidol.
Melatonin
The risk or severity of adverse effects can be increased when Haloperidol is combined with Melatonin.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.
Memantine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Memantine.
Meperidine
The metabolism of Pethidine can be decreased when combined with Haloperidol.
Mephentermine
Haloperidol may decrease the stimulatory activities of Mephentermine.
Mephenytoin
The metabolism of Mephenytoin can be decreased when combined with Haloperidol.
Mephobarbital
The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenobarbital.
Mepivacaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Mepivacaine.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Haloperidol.
Mequitazine
Haloperidol may increase the arrhythmogenic activities of Mequitazine.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Haloperidol.
Mesoridazine
The metabolism of Mesoridazine can be decreased when combined with Haloperidol.
Metaxalone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Metaxalone.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Haloperidol.
Methadone
Methadone may increase the QTc-prolonging activities of Haloperidol.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Methadyl Acetate.
Methamphetamine
The metabolism of Methamphetamine can be decreased when combined with Haloperidol.
Methapyrilene
The risk or severity of adverse effects can be increased when Haloperidol is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Methaqualone.
Methocarbamol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Methocarbamol.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Haloperidol.
Methotrimeprazine
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane
The metabolism of Methoxyflurane can be decreased when combined with Haloperidol.
Methsuximide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Methsuximide.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Haloperidol.
Methylphenidate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
Methyprylon
The metabolism of Methyprylon can be decreased when combined with Haloperidol.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Haloperidol.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Haloperidol.
Metronidazole
Metronidazole may increase the QTc-prolonging activities of Haloperidol.
Metylperon
The risk or severity of adverse effects can be increased when Haloperidol is combined with Melperone.
Metyrosine
Haloperidol may increase the sedative activities of Metyrosine.
Mexiletine
The metabolism of Haloperidol can be decreased when combined with Mexiletine.
Mianserin
The metabolism of Mianserin can be decreased when combined with Haloperidol.
Midazolam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Midazolam.
Midostaurin
The metabolism of Haloperidol can be decreased when combined with Midostaurin.
Mifepristone
Mifepristone may increase the QTc-prolonging activities of Haloperidol.
Milnacipran
The risk or severity of adverse effects can be increased when Haloperidol is combined with Milnacipran.
Minaprine
The metabolism of Minaprine can be decreased when combined with Haloperidol.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Mirabegron
The metabolism of Mirabegron can be decreased when combined with Haloperidol.
Mirtazapine
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mitotane
The serum concentration of Haloperidol can be decreased when it is combined with Mitotane.
Moclobemide
The metabolism of Moclobemide can be decreased when combined with Haloperidol.
Modafinil
The metabolism of Haloperidol can be decreased when combined with Modafinil.
Moexipril
Moexipril may increase the QTc-prolonging activities of Haloperidol.
Molindone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Molindone.
Morphine
The metabolism of Morphine can be decreased when combined with Haloperidol.
Moxifloxacin
Moxifloxacin may increase the QTc-prolonging activities of Haloperidol.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Haloperidol.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Haloperidol.
Nalbuphine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Nalbuphine.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Haloperidol.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Haloperidol.
Naratriptan
The risk or severity of adverse effects can be increased when Naratriptan is combined with Haloperidol.
Nateglinide
The metabolism of Nateglinide can be decreased when combined with Haloperidol.
Nebivolol
The serum concentration of Nebivolol can be increased when it is combined with Haloperidol.
Nefazodone
The metabolism of Haloperidol can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Haloperidol can be decreased when combined with Nelfinavir.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Haloperidol.
Netupitant
The serum concentration of Haloperidol can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Haloperidol can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Haloperidol can be decreased when combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Haloperidol.
Nicotine
The metabolism of Nicotine can be decreased when combined with Haloperidol.
Nicotine Polacrilex
The metabolism of Nicotine can be decreased when combined with Haloperidol.
Nifedipine
The metabolism of Nifedipine can be decreased when combined with Haloperidol.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Haloperidol.
Nilotinib
Haloperidol may increase the QTc-prolonging activities of Nilotinib.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Haloperidol.
Nintedanib
The serum concentration of Nintedanib can be increased when it is combined with Haloperidol.
Nitrazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrazepam.
Nitrofurazone
The metabolism of Nitrofural can be decreased when combined with Haloperidol.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrous oxide.
Nordazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Nordazepam.
Norfloxacin
Norfloxacin may increase the QTc-prolonging activities of Haloperidol.
Norflurane
The risk or severity of adverse effects can be increased when Haloperidol is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Normethadone.
Nortriptyline
The metabolism of Nortriptyline can be decreased when combined with Haloperidol.
Octreotide
Octreotide may increase the QTc-prolonging activities of Haloperidol.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Haloperidol.
Ofloxacin
Haloperidol may increase the QTc-prolonging activities of Ofloxacin.
Olanzapine
The metabolism of Olanzapine can be decreased when combined with Haloperidol.
Olaparib
The metabolism of Haloperidol can be decreased when combined with Olaparib.
Olodaterol
Olodaterol may increase the QTc-prolonging activities of Haloperidol.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Haloperidol.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol.
Omeprazole
The metabolism of Haloperidol can be decreased when combined with Omeprazole.
Ondansetron
Haloperidol may increase the QTc-prolonging activities of Ondansetron.
Opium
The risk or severity of adverse effects can be increased when Haloperidol is combined with Opium.
Orphenadrine
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Haloperidol can be increased when it is combined with Osimertinib.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.
Oxazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Oxazepam.
Oxprenolol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Oxprenolol.
Oxycodone
The metabolism of Oxycodone can be decreased when combined with Haloperidol.
Oxymorphone
The metabolism of Oxymorphone can be decreased when combined with Haloperidol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Haloperidol.
Oxytocin
Oxytocin may increase the QTc-prolonging activities of Haloperidol.
p-Hydroxyamphetamine
Haloperidol may decrease the stimulatory activities of Hydroxyamphetamine.
Palbociclib
The serum concentration of Haloperidol can be increased when it is combined with Palbociclib.
Paliperidone
Haloperidol may increase the QTc-prolonging activities of Paliperidone.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Haloperidol.
Palonosetron
The metabolism of Palonosetron can be decreased when combined with Haloperidol.
Panobinostat
The serum concentration of Haloperidol can be increased when it is combined with Panobinostat.
Pantoprazole
The metabolism of Haloperidol can be decreased when combined with Pantoprazole.
Paraldehyde
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Haloperidol.
Paregoric
The metabolism of Morphine can be decreased when combined with Haloperidol.
Paroxetine
The metabolism of Haloperidol can be decreased when combined with Paroxetine.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Haloperidol.
Pasireotide
Pasireotide may increase the QTc-prolonging activities of Haloperidol.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Haloperidol.
Peginterferon Alfa-2b
The serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.
Pentamidine
Haloperidol may increase the QTc-prolonging activities of Pentamidine.
Pentazocine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine.
Pentobarbital
The metabolism of Haloperidol can be increased when combined with Pentobarbital.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Perazine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Perazine.
Perflutren
Haloperidol may increase the QTc-prolonging activities of Perflutren.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Haloperidol.
Perhexiline
The metabolism of Perhexiline can be decreased when combined with Haloperidol.
Perphenazine
The metabolism of Perphenazine can be decreased when combined with Haloperidol.
Phenacetin
The metabolism of Phenacetin can be decreased when combined with Haloperidol.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.
Phenformin
The metabolism of Phenformin can be decreased when combined with Haloperidol.
Phenobarbital
The metabolism of Haloperidol can be increased when combined with Phenobarbital.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Haloperidol is combined with Phenoxyethanol.
Phentermine
Haloperidol may decrease the stimulatory activities of Phentermine.
PHENTERMINE RESIN
Haloperidol may decrease the stimulatory activities of Phentermine.
Phenylacetic Acid
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Haloperidol.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Haloperidol.
Phenylbutyrate
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Haloperidol.
Phenytoin
The metabolism of Haloperidol can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Haloperidol.
Pimozide
Haloperidol may increase the QTc-prolonging activities of Pimozide.
Pindolol
The metabolism of Pindolol can be decreased when combined with Haloperidol.
Pipamperone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Pipamperone.
Piperazine
The metabolism of Piperazine can be decreased when combined with Haloperidol.
Pipothiazine
The metabolism of Pipotiazine can be decreased when combined with Haloperidol.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Haloperidol.
Piribedil
The therapeutic efficacy of Haloperidol can be decreased when used in combination with Piribedil.
Pirinitramide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Piritramide.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Haloperidol.
Pizotyline
The risk or severity of adverse effects can be increased when Haloperidol is combined with Pizotifen.
Pomalidomide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Pomalidomide.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Haloperidol.
Posaconazole
The metabolism of Haloperidol can be decreased when combined with Posaconazole.
Pramipexole
Haloperidol may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Pramocaine.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Haloperidol.
Prazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Prazepam.
Pregabalin
The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Prilocaine.
Primaquine
Haloperidol may increase the QTc-prolonging activities of Primaquine.
Primidone
The metabolism of Haloperidol can be increased when combined with Primidone.
Procainamide
Haloperidol may increase the QTc-prolonging activities of Procainamide.
Procaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Procaine.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Haloperidol.
Prochlorperazine
The metabolism of Prochlorperazine can be decreased when combined with Haloperidol.
Progesterone
The metabolism of Progesterone can be decreased when combined with Haloperidol.
Promazine
Promazine may increase the QTc-prolonging activities of Haloperidol.
Promethazine
The metabolism of Promethazine can be decreased when combined with Haloperidol.
Propafenone
The serum concentration of Haloperidol can be increased when it is combined with Propafenone.
Proparacaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Proparacaine.
Propofol
The metabolism of Propofol can be decreased when combined with Haloperidol.
Propoxyphene
The risk or severity of adverse effects can be increased when Haloperidol is combined with Dextropropoxyphene.
Propranolol
The metabolism of Propranolol can be decreased when combined with Haloperidol.
Protriptyline
The metabolism of Protriptyline can be decreased when combined with Haloperidol.
Pseudoephedrine
The metabolism of Pseudoephedrine can be decreased when combined with Haloperidol.
Pyrimethamine
The metabolism of Haloperidol can be decreased when combined with Pyrimethamine.
Quazepam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Quazepam.
Quetiapine
Haloperidol may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Haloperidol may increase the QTc-prolonging activities of Quetiapine.
Quinagolide
The therapeutic efficacy of Quinagolide can be decreased when used in combination with Haloperidol.
Quinidine
Haloperidol may increase the QTc-prolonging activities of Quinidine.
Quinine
Haloperidol may increase the QTc-prolonging activities of Quinine.
Ramelteon
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ramelteon.
Ranitidine
The metabolism of Ranitidine can be decreased when combined with Haloperidol.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Haloperidol.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.
Remifentanil
The risk or severity of adverse effects can be increased when Haloperidol is combined with Remifentanil.
Remoxipride
The metabolism of Remoxipride can be decreased when combined with Haloperidol.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Haloperidol.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.
Ribociclib
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Haloperidol.
Rifabutin
The metabolism of Haloperidol can be increased when combined with Rifabutin.
Rifampin
The metabolism of Haloperidol can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Haloperidol can be increased when combined with Rifapentine.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Haloperidol.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Haloperidol.
Risperidone
The metabolism of Risperidone can be decreased when combined with Haloperidol.
Ritonavir
The metabolism of Haloperidol can be decreased when combined with Ritonavir.
Rizatriptan
The risk or severity of adverse effects can be increased when Rizatriptan is combined with Haloperidol.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Haloperidol.
Rolapitant
The metabolism of Haloperidol can be decreased when combined with Rolapitant.
Ropinirole
Haloperidol may increase the sedative activities of Ropinirole.
Ropivacaine
The metabolism of Ropivacaine can be decreased when combined with Haloperidol.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Haloperidol.
Rotigotine
Haloperidol may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Rucaparib can be decreased when combined with Haloperidol.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Haloperidol.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Haloperidol.
Salmeterol
Salmeterol may increase the QTc-prolonging activities of Haloperidol.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Haloperidol.
Saquinavir
The metabolism of Haloperidol can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Haloperidol can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Haloperidol can be decreased when used in combination with Sarilumab.
Scopolamine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Scopolamine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Scopolamine.
Secobarbital
The metabolism of Haloperidol can be increased when combined with Secobarbital.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Haloperidol.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Haloperidol.
Sertindole
The metabolism of Sertindole can be decreased when combined with Haloperidol.
Sertraline
The metabolism of Sertraline can be decreased when combined with Haloperidol.
Sevoflurane
The risk or severity of adverse effects can be increased when Haloperidol is combined with Sevoflurane.
Sildenafil
The metabolism of Haloperidol can be decreased when combined with Sildenafil.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Haloperidol.
Siltuximab
The serum concentration of Haloperidol can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Haloperidol can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Haloperidol.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Solifenacin
Solifenacin may increase the QTc-prolonging activities of Haloperidol.
Sorafenib
The metabolism of Haloperidol can be decreased when combined with Sorafenib.
Sotalol
Haloperidol may increase the QTc-prolonging activities of Sotalol.
ST. JOHN'S WORT EXTRACT
The serum concentration of Haloperidol can be decreased when it is combined with St. John's Wort.
Sufentanil
The risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.
Sulfadiazine
The metabolism of Haloperidol can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Haloperidol can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Haloperidol.
Sulfisoxazole
The metabolism of Haloperidol can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Haloperidol.
Sulpiride
Haloperidol may increase the antipsychotic activities of Sulpiride.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Haloperidol.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Haloperidol.
Sunitinib
Sunitinib may increase the QTc-prolonging activities of Haloperidol.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Haloperidol.
Suvorexant
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tamoxifen
The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Haloperidol resulting in a loss in efficacy.
Tamsulosin
The metabolism of Tamsulosin can be decreased when combined with Haloperidol.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Tasimelteon
The risk or severity of adverse effects can be increased when Haloperidol is combined with Tasimelteon.
Tedizolid
The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Haloperidol.
Tedizolid Phosphate
The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Haloperidol.
Tegaserod
The metabolism of Tegaserod can be decreased when combined with Haloperidol.
Telaprevir
The metabolism of Haloperidol can be decreased when combined with Telaprevir.
Telavancin
Haloperidol may increase the QTc-prolonging activities of Telavancin.
Telithromycin
The metabolism of Haloperidol can be decreased when combined with Telithromycin.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol.
Tenofovir Disoproxil
The metabolism of Haloperidol can be decreased when combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Haloperidol.
Terbinafine
The metabolism of Haloperidol can be decreased when combined with Terbinafine.
Terbutaline
Terbutaline may increase the QTc-prolonging activities of Haloperidol.
Terbutaline Sulfate
Terbutaline may increase the QTc-prolonging activities of Haloperidol.
Terfenadine
The metabolism of Terfenadine can be decreased when combined with Haloperidol.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Haloperidol.
Tetrabenazine
The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Haloperidol.
Tetracaine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Haloperidol is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Thalidomide
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Theophylline
The metabolism of Haloperidol can be decreased when combined with Theophylline.
Theophylline anhydrous
The metabolism of Haloperidol can be decreased when combined with Theophylline.
Thiamylal
The risk or severity of adverse effects can be increased when Haloperidol is combined with Thiamylal.
Thiopental
The risk or severity of adverse effects can be increased when Haloperidol is combined with Thiopental.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Haloperidol is combined with Thiopental.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Haloperidol.
Thiothixene
The risk or severity of adverse effects can be increased when Haloperidol is combined with Thiothixene.
Tiagabine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Tiagabine.
Tiapride
The risk or severity of adverse effects can be increased when Haloperidol is combined with Tiapride.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.
Ticagrelor
The metabolism of Haloperidol can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Haloperidol can be decreased when combined with Ticlopidine.
Timolol
The metabolism of Timolol can be decreased when combined with Haloperidol.
Timolol Anhydrous
The metabolism of Timolol can be decreased when combined with Haloperidol.
Tiotropium
The metabolism of Tiotropium can be decreased when combined with Haloperidol.
Tipranavir
The metabolism of Haloperidol can be decreased when combined with Tipranavir.
Tizanidine
Tizanidine may increase the QTc-prolonging activities of Haloperidol.
Tocilizumab
The serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.
Tolbutamide
The metabolism of Haloperidol can be decreased when combined with Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Tolcapone.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Haloperidol.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.
Tolterodine
The metabolism of Tolterodine can be decreased when combined with Haloperidol.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Haloperidol.
Topiramate
The metabolism of Haloperidol can be decreased when combined with Topiramate.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Haloperidol.
Toremifene
Haloperidol may increase the QTc-prolonging activities of Toremifene.
Trabectedin
The metabolism of Trabectedin can be decreased when combined with Haloperidol.
Tramadol
The therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Haloperidol.
Tranylcypromine
The metabolism of Haloperidol can be decreased when combined with Tranylcypromine.
Trazodone
The metabolism of Trazodone can be decreased when combined with Haloperidol.
Treprostinil
Treprostinil may increase the QTc-prolonging activities of Haloperidol.
Triazolam
The risk or severity of adverse effects can be increased when Haloperidol is combined with Triazolam.
Triazulenone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Loprazolam.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Haloperidol.
Trifluoperazine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Trifluoperazine.
Triflupromazine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Triflupromazine.
Trimethoprim
The metabolism of Haloperidol can be decreased when combined with Trimethoprim.
Trimipramine
The metabolism of Trimipramine can be decreased when combined with Haloperidol.
Triprolidine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Triprolidine.
Triptorelin
Triptorelin may increase the QTc-prolonging activities of Haloperidol.
Umeclidinium
The metabolism of Umeclidinium can be decreased when combined with Haloperidol.
Urethane
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl carbamate.
Valbenazine
The metabolism of Valbenazine can be decreased when combined with Haloperidol.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Haloperidol.
Valproate
The risk or severity of adverse effects can be increased when Haloperidol is combined with Valproic Acid.
Valproic Acid
The risk or severity of adverse effects can be increased when Haloperidol is combined with Valproic Acid.
Valsartan
The metabolism of Haloperidol can be decreased when combined with Valsartan.
Vandetanib
Haloperidol may increase the QTc-prolonging activities of Vandetanib.
Vardenafil
Vardenafil may increase the QTc-prolonging activities of Haloperidol.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Haloperidol.
Venlafaxine
The metabolism of Haloperidol can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Haloperidol can be decreased when combined with Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Haloperidol is combined with Vigabatrin.
Vilanterol
Vilanterol may increase the QTc-prolonging activities of Haloperidol.
Vilazodone
The metabolism of Vilazodone can be decreased when combined with Haloperidol.
Vinblastine
The metabolism of Vinblastine can be decreased when combined with Haloperidol.
Vincristine
The excretion of Vincristine can be decreased when combined with Haloperidol.
Vinorelbine
The metabolism of Vinorelbine can be decreased when combined with Haloperidol.
Voriconazole
The metabolism of Haloperidol can be decreased when combined with Voriconazole.
Vorinostat
Vorinostat may increase the QTc-prolonging activities of Haloperidol.
Vortioxetine
The metabolism of Vortioxetine can be decreased when combined with Haloperidol.
Xylazine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Xylazine.
Yohimbine
The metabolism of Yohimbine can be decreased when combined with Haloperidol.
Zafirlukast
The metabolism of Haloperidol can be decreased when combined with Zafirlukast.
Zalcitabine
The metabolism of Zalcitabine can be decreased when combined with Haloperidol.
Zaleplon
The risk or severity of adverse effects can be increased when Haloperidol is combined with Zaleplon.
Ziconotide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Ziconotide.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Haloperidol.
Ziprasidone
Haloperidol may increase the QTc-prolonging activities of Ziprasidone.
Zolmitriptan
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Haloperidol.
Zolpidem
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Haloperidol.
Zonisamide
The risk or severity of adverse effects can be increased when Haloperidol is combined with Zonisamide.
Zopiclone
The risk or severity of adverse effects can be increased when Haloperidol is combined with Zopiclone.
Zotepine
The risk or severity of adverse effects can be increased when Haloperidol is combined with Zotepine.
Zuclopenthixol
Haloperidol may increase the QTc-prolonging activities of Zuclopenthixol.
